Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: 

RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 2
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis BJID
Pedral-Sampaio,Diana B.; Alves,Carmosina R.; Netto,Eduardo M.; Brites,Carlos; Oliveira,Adriano S.; Badaro,Roberto.
Forty-nine AIDS patients, most of who were antiretroviral therapy (ARV) naïve, with active tuberculosis, were treated with Rifampin 600mg, Isoniazid 400mg and Pirazinamide 2g daily. They also received ARV, consisting of Efavirenz (600mg/day) plus 2 NRTIs. All patients were prospectively followed for at least 24 months. Baselines were: male/female ratio 2:1, mean age 34.7 ± 9.4 yrs; weight 51 ± 9.0 kg, viral load 5.6 ± 0.6 logs, CD4 cell count 101 ± 128 cells/ mm³. Follow up mean values of data logs of VL and CD4+ cell /mm³ counts were: VL 1.7 and CD4+ 265; VL 1.3 and CD4+ 251; VL 1.4 and CD4+ 326 at 6, 12 and 24 months, respectively. Weight gain changes were: 5 ± 9.9 ± 12 and 21 ± 16 kg respectively at 6, 12 and 24 months. A non-concomitant ARV regimen was...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Tuberculosis; HIV/AIDS; Drug interaction; Rifampin; Efavirenz; Antiretroviral therapy.
Ano: 2004 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702004000300004
Imagem não selecionada

Imprime registro no formato completo
Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: a case report BJID
Badaro,Roberto; Lobo,Iza; Nakatani,Maria; Muiños,Alvaro; M. Netto,Eduardo; Coler,Rhea N.; Reed,Steven G..
Immunotherapy has been proposed as a method to treat mucosal leishmaniasis for many years, but the approach has been hampered by poor definition and variability of antigens used, and results have been inconclusive. We report here a case of antimonial-refractory mucosal leishmaniasis in a 45 year old male who was treated with three single injections (one per month) with a cocktail of four Leishmania recombinant antigens selected after documented hypo-responsiveness of the patient to these antigens, plus 50mg of GM-CSF as vaccine adjuvant. Three months after treatment, all lesions had resolved completely and the patient remains without relapse after two years. Side effects of the treatment included only moderate erythema and induration at the injection site...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Leishmaniasis; Immunotherapy; Mucosal leishmaniasis.
Ano: 2001 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702001000400008
Registros recuperados: 2
Primeira ... 1 ... Última
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional